BioWorld

Dec. 1, 2006

View Archived Issues

Durect, Nycomed Agree On Pain Drug Marketing Deal

Shares of Durect Corp. rose nearly 50 percent in after-close trading Wednesday based on a $202 million marketing deal between the Cupertino, Calif.-based company and Roskilde, Denmark-based Nycomed A/S. (BioWorld Today) Read More

Still Silent, Concert Pharma Raising $48.5M In Series B

Read More

Biota, Boehringer Partner HCV Nucleoside Program For $102M

Read More

Cancer Company Xanthus Adding $25M Via Series B

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Appointments And Advancements

Read More